Article

Michelle Esser Discusses Two Encouraging Breast Cancer Studies

Author(s):

Michelle Esser

Michelle Esser, program manager for research and advocacy, Young Survival Coalition, discusses two encouraging studies presented during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).

Michelle Esser, program manager for research and advocacy, Young Survival Coalition, discusses two encouraging studies presented during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a Chicago gathering of nearly 30,000 oncology professionals in May and June.

Esser was particularly encouraged by discussions surrounding ovarian suppression, surgery and bisphosphonate use in premenopausal women with breast cancer. Esser also mentions a study conducted by Hatem Abdel Azim that looked at genetic differences in breast cancer of young and older women.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content
Illustration of Laura.
April 29th 2025

A Fellow Cancer Survivor Gives Me a Useful Message

Laura Yeager
A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Felicia Mitchell is a survivor of stage 2b HER2-positive breast cancer diagnosed in 2010. Catch up on all of Felicia's blogs here!
April 28th 2025

How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer

Felicia Mitchell
I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
The combination of Enhertu plus Perjeta showed improvement in progression-free survival versus standard treatment among patients with HER2-positive metastatic breast cancer.
April 21st 2025

Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer

Ryan Scott
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.
Trodelvy plus Keytruda was associated with an improvement in disease progression in mTNBC: © stock.adobe.com.
April 21st 2025

Trodelvy Plus Keytruda May Slow Progression in mTNBC

Alex Biese
In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.